Neuroendocrine Tumor Therapy Response Assessment.
PET Clin
; 18(2): 267-286, 2023 Apr.
Article
en En
| MEDLINE
| ID: mdl-36858748
ABSTRACT
Peptide receptor radionuclide therapy has become an integral part of management of neuroendocrine neoplasms. Gallium-68- and lutetium-177-labeled somatostatin receptor analogues have replaced yttrium-90- and 111-indium-based tracers. Several newer targeted therapies are also being used in clinical and research settings. It is imperative to accurately evaluate the response to these agents. The characteristics of NENs and the response patterns of the targeted therapies make response assessment in this group challenging. This article provides an overview of the strengths and weaknesses of the various biomarkers available for response assessment.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tumores Neuroendocrinos
Límite:
Humans
Idioma:
En
Revista:
PET Clin
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos